{
  "symbol": "ADXN",
  "company_name": "Addex Therapeutics Ltd ADR",
  "ir_website": "https://www.addextherapeutics.com/en/investors/",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Press releases",
          "url": "https://www.addextherapeutics.com/en/media/press-releases/",
          "content": "# [![Addex](/themes/application/assets/media/images/addex-logo.svg)](/)\n\n## Allosteric modulators for **human health**\n\n# Press releases\n\nAll Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 Please select year\n\n  * 11.222024\n\n### [Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update](https://www.addextherapeutics.com/en/investors/press-releases/addex-reports-third-quarter-2024-financial-results-and-provides-corporate-update/)\n\n[ ](https://www.addextherapeutics.com/en/investors/press-releases/addex-reports-third-quarter-2024-financial-results-and-provides-corporate-update/ \"Read more\")\n\n\n\n  * 11.112024\n\n### [Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024](https://www.addextherapeutics.com/en/investors/press-releases/addex-provisional-2024-third-quarter-results-showed-net-loss-compared-second-quarter-2024/)\n\n[ ](https://www.addextherapeutics.com/en/investors/press-releases/addex-provisional-2024-third-quarter-results-showed-net-loss-compared-second-quarter-2024/ \"Read more\")\n\n\n\n  * 09.302024\n\n### [Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update](https://www.addextherapeutics.com/en/investors/press-releases/addex-therapeutics-reports-2024-half-year-and-second-quarter-financial-results-and-provides-corporate-update/)\n\n[ ](https://www.addextherapeutics.com/en/investors/press-releases/addex-therapeutics-reports-2024-half-year-and-second-quarter-financial-results-and-provides-corporate-update/ \"Read more\")\n\n\n\n  * 09.192024\n\n### [Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit](https://www.addextherapeutics.com/en/investors/press-releases/addex-provisional-2024-half-year-and-second-quarter-result-increased-net-loss-net-profit/)\n\n[ ](https://www.addextherapeutics.com/en/investors/press-releases/addex-provisional-2024-half-year-and-second-quarter-result-increased-net-loss-net-profit/ \"Read more\")\n\n\n\n  * 09.042024\n\n### [Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference](https://www.addextherapeutics.com/en/investors/press-releases/addex-participate-hc-wainwright-26th-annual-global-investment-conference/)\n\n[ ](https://www.addextherapeutics.com/en/investors/press-releases/addex-participate-hc-wainwright-26th-annual-global-investment-conference/ \"Read more\")\n\n\n\n  * 08.272024\n\n### [Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration](https://www.addextherapeutics.com/en/investors/press-releases/addex-and-indivior-select-clinical-candidates-gabab-positive-allosteric-modulator-research-collaboration/)\n\n[ ](https://www.addextherapeutics.com/en/investors/press-releases/addex-and-indivior-select-clinical-candidates-gabab-positive-allosteric-modulator-research-collaboration/ \"Read more\")\n\n\n\n  * 07.222024\n\n### [Addexâ€™s Partner Discontinues ADX71149 development in Epilepsy](https://www.addextherapeutics.com/en/investors/press-releases/addexs-partner-discontinues-adx71149-development-epilepsy/)\n\n[ ](https://www.addextherapeutics.com/en/investors/press-releases/addexs-partner-discontinues-adx71149-development-epilepsy/ \"Read more\")\n\n\n\n  * 07.152024\n\n### [Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)](https://www.addextherapeutics.com/en/investors/press-releases/addex-presents-positive-results-gabab-pam-cough-program-thirteenth-london-international-cough-symposium-13th-lics/)\n\n[ ](https://www.addextherapeutics.com/en/investors/press-releases/addex-presents-positive-results-gabab-pam-cough-program-thirteenth-london-international-cough-symposium-13th-lics/ \"Read more\")\n\n\n\n  * 07.122024\n\n### [Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)](https://www.addextherapeutics.com/en/investors/press-releases/addex-present-thirteenth-london-international-cough-symposium-13th-lics/)\n\n[ ](https://www.addextherapeutics.com/en/investors/press-releases/addex-present-thirteenth-london-international-cough-symposium-13th-lics/ \"Read more\")\n\n\n\n  * 07.012024\n\n### [Addex Shareholders Approve All Resolutions at Annual General Meeting](https://www.addextherapeutics.com/en/investors/press-releases/addex-shareholders-approve-all-resolutions-annual-general-meeting6/)\n\n[ ](https://www.addextherapeutics.com/en/investors/press-releases/addex-shareholders-approve-all-resolutions-annual-general-meeting6/ \"Read more\")\n\n\n\n\n  * [1](/en/media/press-releases/?ccm_paging_p_b2214=1)\n  * [2](/en/media/press-releases/?ccm_paging_p_b2214=2)\n  * ...\n  * [3](/en/media/press-releases/?ccm_paging_p_b2214=3)\n  * [4](/en/media/press-releases/?ccm_paging_p_b2214=4)\n  * [5](/en/media/press-releases/?ccm_paging_p_b2214=5)\n  * [6](/en/media/press-releases/?ccm_paging_p_b2214=6)\n  * [7](/en/media/press-releases/?ccm_paging_p_b2214=7)\n  * [8](/en/media/press-releases/?ccm_paging_p_b2214=8)\n  * [9](/en/media/press-releases/?ccm_paging_p_b2214=9)\n  * [10](/en/media/press-releases/?ccm_paging_p_b2214=10)\n  * [11](/en/media/press-releases/?ccm_paging_p_b2214=11)\n  * [12](/en/media/press-releases/?ccm_paging_p_b2214=12)\n  * [13](/en/media/press-releases/?ccm_paging_p_b2214=13)\n  * [14](/en/media/press-releases/?ccm_paging_p_b2214=14)\n  * [15](/en/media/press-releases/?ccm_paging_p_b2214=15)\n  * [16](/en/media/press-releases/?ccm_paging_p_b2214=16)\n  * [17](/en/media/press-releases/?ccm_paging_p_b2214=17)\n  * [18](/en/media/press-releases/?ccm_paging_p_b2214=18)\n  * [19](/en/media/press-releases/?ccm_paging_p_b2214=19)\n  * [20](/en/media/press-releases/?ccm_paging_p_b2214=20)\n  * [21](/en/media/press-releases/?ccm_paging_p_b2214=21)\n  * [22](/en/media/press-releases/?ccm_paging_p_b2214=22)\n  * [23](/en/media/press-releases/?ccm_paging_p_b2214=23)\n  * [24](/en/media/press-releases/?ccm_paging_p_b2214=24)\n  * [25](/en/media/press-releases/?ccm_paging_p_b2214=25)\n  * [26](/en/media/press-releases/?ccm_paging_p_b2214=26)\n  * [27](/en/media/press-releases/?ccm_paging_p_b2214=27)\n  * [28](/en/media/press-releases/?ccm_paging_p_b2214=28)\n  * [29](/en/media/press-releases/?ccm_paging_p_b2214=29)\n  * [30](/en/media/press-releases/?ccm_paging_p_b2214=30)\n  * [31](/en/media/press-releases/?ccm_paging_p_b2214=31)\n  * [32](/en/media/press-releases/?ccm_paging_p_b2214=32)\n  * [33](/en/media/press-releases/?ccm_paging_p_b2214=33)\n  * [34](/en/media/press-releases/?ccm_paging_p_b2214=34)\n  * [35](/en/media/press-releases/?ccm_paging_p_b2214=35)\n  * [36](/en/media/press-releases/?ccm_paging_p_b2214=36)\n  * [37](/en/media/press-releases/?ccm_paging_p_b2214=37)\n  * [38](/en/media/press-releases/?ccm_paging_p_b2214=38)\n  * [39](/en/media/press-releases/?ccm_paging_p_b2214=39)\n  * [40](/en/media/press-releases/?ccm_paging_p_b2214=40)\n  * [41](/en/media/press-releases/?ccm_paging_p_b2214=41)\n  * [42](/en/media/press-releases/?ccm_paging_p_b2214=42)\n  * [43](/en/media/press-releases/?ccm_paging_p_b2214=43)\n\n[Next](/en/media/press-releases/?ccm_paging_p_b2214=2)\n\n\n\n\n[ Back ](/en/media/)\n"
        }
      ]
    },
    {
      "section_name": "Financial Reports",
      "links": [
        {
          "title": "Financial Reports",
          "url": "https://www.addextherapeutics.com/en/investors/financial-reports/",
          "content": "# [![Addex](/themes/application/assets/media/images/addex-logo.svg)](/)\n\n## Allosteric modulators for **human health**\n\n# Financial Reports\n\n  * 2024 Annual Report & [Quarter 3 Report](https://www.addextherapeutics.com/index.php/download_file/418/) & [Half Year Report](https://www.addextherapeutics.com/index.php/download_file/417/) & [Quarter 1 Report](\thttps://www.addextherapeutics.com/index.php/download_file/414/)\n  * 2023 [Annual Report](https://www.addextherapeutics.com/index.php/download_file/409/) & [Quarter 3 Report](https://www.addextherapeutics.com/index.php/download_file/402/) & [Half Year Report](https://www.addextherapeutics.com/index.php/download_file/398/) & [Quarter 1 Report](https://www.addextherapeutics.com/index.php/download_file/395/)\n  * 2022 [Annual Report](https://www.addextherapeutics.com/index.php/download_file/389/) & [Quarter 3 Report](https://www.addextherapeutics.com/index.php/download_file/394/) & [Half Year Report](https://www.addextherapeutics.com/index.php/download_file/383/) & [Quarter 1 Report](https://www.addextherapeutics.com/index.php/download_file/373/)\n  * 2021 [Annual Report](https://www.addextherapeutics.com/index.php/download_file/371/) & [Quarter 3 Report](https://www.addextherapeutics.com/index.php/download_file/369/) & [Half Year Report](https://www.addextherapeutics.com/index.php/download_file/367/) & [Quarter 1 Report](https://www.addextherapeutics.com/index.php/download_file/347/)\n  * 2020 [Annual Report](https://www.addextherapeutics.com/index.php/download_file/340/) & [Quarter 3 Report](https://www.addextherapeutics.com/index.php/download_file/335/) & [Half Year Report](https://www.addextherapeutics.com/index.php/download_file/325/) & [Quarter 1 Report](https://www.addextherapeutics.com/index.php/download_file/304/)\n  * 2019 [Annual Report](https://www.addextherapeutics.com/index.php/download_file/336/) & [Half Year Report](https://www.addextherapeutics.com/index.php/download_file/324/)\n  * 2018 [Annual Report](https://www.addextherapeutics.com/index.php/download_file/220/) & [Half Year Report](https://www.addextherapeutics.com/index.php/download_file/187/)\n  * 2017 [Annual Report](https://www.addextherapeutics.com/index.php/download_file/163/) & [Half Year Report](https://www.addextherapeutics.com/index.php/download_file/66/)\n  * 2016 [Annual Report](https://www.addextherapeutics.com/index.php/download_file/51/) & [Half Year Report](https://www.addextherapeutics.com/index.php/download_file/67/)\n  * 2015 [Annual Report](https://www.addextherapeutics.com/index.php/download_file/52/) & [Half Year Report](https://www.addextherapeutics.com/index.php/download_file/68/)[](https://www.addextherapeutics.com/index.php/download_file/68/)\n  * 2014 [Annual Report](https://www.addextherapeutics.com/index.php/download_file/53/) & [Half Year Report](https://www.addextherapeutics.com/index.php/download_file/69/)\n  * 2013 [Annual Report](https://www.addextherapeutics.com/index.php/download_file/54/) & [Half Year Report](https://www.addextherapeutics.com/index.php/download_file/70/)[](https://www.addextherapeutics.com/index.php/download_file/70/)\n  * 2012 [Annual Report](https://www.addextherapeutics.com/index.php/download_file/55/) & [Half Year Report](https://www.addextherapeutics.com/index.php/download_file/71/)[](https://www.addextherapeutics.com/index.php/download_file/71/)\n  * 2011 [Annual Report](https://www.addextherapeutics.com/index.php/download_file/56/) & [Half Year Report](https://www.addextherapeutics.com/index.php/download_file/72/)\n  * 2010 [Annual Report](https://www.addextherapeutics.com/index.php/download_file/132/) & [Half Year Report](https://www.addextherapeutics.com/index.php/download_file/73/)\n  * 2009 [Annual Report](https://www.addextherapeutics.com/index.php/download_file/58/) & [Half Year Report](https://www.addextherapeutics.com/index.php/download_file/74/)\n  * 2008 [Annual Report](\thttps://www.addextherapeutics.com/index.php/download_file/137/) & [Half Year Report](https://www.addextherapeutics.com/index.php/download_file/75/)\n  * 2007 [Annual Report](https://www.addextherapeutics.com/index.php/download_file/60/) & [Half Year Report](https://www.addextherapeutics.com/index.php/download_file/76/)\n\n\n"
        }
      ]
    },
    {
      "section_name": "Analyst Reports",
      "links": [
        {
          "title": "Analyst Reports",
          "url": "https://www.addextherapeutics.com/en/investors/analyst-reports/",
          "content": "# [![Addex](/themes/application/assets/media/images/addex-logo.svg)](/)\n\n## Allosteric modulators for **human health**\n\n# Analyst Reports\n\n  * [Van Leewenhoeck Jul-2020](https://www.addextherapeutics.com/index.php/download_file/322/)\n  * [Van Leewenhoeck Dec-2019](https://www.addextherapeutics.com/index.php/download_file/252/)\n  * [Van Leewenhoeck Aug-2019](https://www.addextherapeutics.com/index.php/download_file/234/)\n  * [Van Leewenhoeck Nov-2018](https://www.addextherapeutics.com/index.php/download_file/193/)\n  * [Van Leewenhoeck Jul-2018](https://www.addextherapeutics.com/index.php/download_file/177/)\n  * [Van Leewenhoeck Feb-2018](https://www.addextherapeutics.com/index.php/download_file/140/)\n  * [ValuationLAB Jan-2018](https://www.addextherapeutics.com/index.php/download_file/131/)\n  * [Van Leewenhoeck Oct-2017](https://www.addextherapeutics.com/index.php/download_file/62/)\n\n\n"
        }
      ]
    },
    {
      "section_name": "General Meetings",
      "links": [
        {
          "title": "General Meetings",
          "url": "https://www.addextherapeutics.com/en/investors/general-meetings/",
          "content": "# [![Addex](/themes/application/assets/media/images/addex-logo.svg)](/)\n\n## Allosteric modulators for **human health**\n\n# General Meetings\n\n  * 2024 AGM [invitation](https://www.addextherapeutics.com/index.php/download_file/413/) & [results](https://www.addextherapeutics.com/index.php/download_file/416/)\n  * 2023 EGM [invitation ](https://www.addextherapeutics.com/index.php/download_file/400/)& [results](https://www.addextherapeutics.com/index.php/download_file/405/)\n  * 2023 AGM [invitation](https://www.addextherapeutics.com/index.php/download_file/393/) & [results](https://www.addextherapeutics.com/index.php/download_file/396/)\n  * 2022 AGM [invitation ](https://www.addextherapeutics.com/index.php/download_file/372/)& [results](https://www.addextherapeutics.com/index.php/download_file/375/)\n  * 2021 AGM [invitation](https://www.addextherapeutics.com/index.php/download_file/351/) & [results](https://www.addextherapeutics.com/index.php/download_file/353/)\n  * 2020 AGM [invitation ](https://www.addextherapeutics.com/index.php/download_file/303/)& [results](https://www.addextherapeutics.com/index.php/download_file/337/)\n  * 2019 AGM [invitation](https://www.addextherapeutics.com/files/6915/6102/4045/AGM_Invitation_2019.pdf) & [results](\thttps://www.addextherapeutics.com/index.php/download_file/229/)\n  * 2018 AGM [invitation](https://www.addextherapeutics.com/index.php/download_file/164/) & [results](https://www.addextherapeutics.com/index.php/download_file/176/)\n  * 2018 EGM [invitation](https://www.addextherapeutics.com/index.php/download_file/146/) & [results](https://www.addextherapeutics.com/index.php/download_file/196/)\n  * 2017 AGM [invitation](https://www.addextherapeutics.com/index.php/download_file/162/) & [results](https://www.addextherapeutics.com/index.php/download_file/165/)\n  * 2016 AGM [invitation](https://www.addextherapeutics.com/index.php/download_file/81/) & [results](https://www.addextherapeutics.com/index.php/download_file/80/)\n  * 2015 AGM [invitation](https://www.addextherapeutics.com/index.php/download_file/83/) & [results](https://www.addextherapeutics.com/index.php/download_file/82/)\n  * 2014 AGM [invitation](https://www.addextherapeutics.com/index.php/download_file/85/) & [results](https://www.addextherapeutics.com/index.php/download_file/166/)\n  * 2013 AGM [invitation](https://www.addextherapeutics.com/index.php/download_file/87/) & [results](https://www.addextherapeutics.com/index.php/download_file/86/)\n  * 2012 AGM [invitation](https://www.addextherapeutics.com/index.php/download_file/89/) & [results](https://www.addextherapeutics.com/index.php/download_file/88/)\n  * 2011 AGM [invitation](https://www.addextherapeutics.com/index.php/download_file/48/) & [results](https://www.addextherapeutics.com/index.php/download_file/49/)\n  * 2010 AGM [invitation](https://www.addextherapeutics.com/index.php/download_file/46/) & [results](https://www.addextherapeutics.com/index.php/download_file/47/)\n  * 2009 AGM [invitation ](https://www.addextherapeutics.com/index.php/download_file/90/)& [results](https://www.addextherapeutics.com/index.php/download_file/45/)\n  * 2008 AGM [invitation ](https://www.addextherapeutics.com/index.php/download_file/44/)& results\n\n\n"
        }
      ]
    },
    {
      "section_name": "SEC / SIX Filings",
      "links": [
        {
          "title": "SEC Filings",
          "url": "https://www.addextherapeutics.com/en/investors/sec-six-filings/",
          "content": "# [![Addex](/themes/application/assets/media/images/addex-logo.svg)](/)\n\n## Allosteric modulators for **human health**\n\n# SEC / SIX Filings\n\n## SEC FILINGS\n\nPlease click below to view / download:\n\n  * [Our SEC Filings](https://www.sec.gov/cgi-bin/browse-edgar?company=addex&owner=exclude&action=getcompany)\n\n\n\n## SIX FILINGS\n\nPlease click below to view / download:\n\n  * [ Latest Prospectus](https://www.addextherapeutics.com/index.php/download_file/370/)[](https://www.sec.gov/cgi-bin/browse-edgar?company=addex&owner=exclude&action=getcompany)\n\n\n"
        }
      ]
    },
    {
      "section_name": "Guide to US ADSS for Six Shareholders",
      "links": [
        {
          "title": "Guide to US ADSS for Six Shareholders",
          "url": "https://www.addextherapeutics.com/en/investors/guide-us-adss-six-shareholders/",
          "content": "# [![Addex](/themes/application/assets/media/images/addex-logo.svg)](/)\n\n## Allosteric modulators for **human health**\n\n# Guide to US ADSS for Six Shareholders\n\n  * [Instructions for Exchanging Listed Shares into Nasdaq-listed ADSs](https://www.addextherapeutics.com/index.php/download_file/399/)\n\n\n"
        }
      ]
    },
    {
      "section_name": "Register for email news",
      "links": [
        {
          "title": "Register for email news",
          "url": "https://www.addextherapeutics.com/en/investors/register-email-news/",
          "content": "# [![Addex](/themes/application/assets/media/images/addex-logo.svg)](/)\n\n## Allosteric modulators for **human health**\n\n# Register for email news\n\nName *  \n---  \nEmail *\n"
        }
      ]
    },
    {
      "section_name": "Corporate Governance",
      "links": [
        {
          "title": "Corporate Governance",
          "url": "https://www.addextherapeutics.com/en/investors/corporate-governance/",
          "content": "# [![Addex](/themes/application/assets/media/images/addex-logo.svg)](/)\n\n## Allosteric modulators for **human health**\n\n# Corporate Governance\n\nBelow are our Corporate policies and our Equity Incentive Plan, please click on the link to view / download:\n\n  * [Related Person Transactions Policy](https://www.addextherapeutics.com/index.php/download_file/270/)\n  * [Organizational Rules](https://www.addextherapeutics.com/index.php/download_file/275/)\n  * [Anti-Corruption Policy](https://www.addextherapeutics.com/index.php/download_file/274/)\n  * [Investment Policy](https://www.addextherapeutics.com/index.php/download_file/273/)\n  * [Whistleblower Policy](https://www.addextherapeutics.com/index.php/download_file/272/)\n  * [Securities Trading Policy](https://www.addextherapeutics.com/index.php/download_file/271/)\n  * [Public Disclosure and Reporting Policy](https://www.addextherapeutics.com/index.php/download_file/280/)\n  * [Equity Incentive Plan](https://www.addextherapeutics.com/index.php/download_file/388/)\n  * [Articles of Association](https://www.addextherapeutics.com/index.php/download_file/354/)\n  * [Board Diversity Matrix](/en/investors/board-diversity-matrix/ \"Board Diversity Matrix\")\n  * [Claw Back Policy](https://www.addextherapeutics.com/index.php/download_file/404/)\n\n\n"
        }
      ]
    },
    {
      "section_name": "Contact",
      "links": [
        {
          "title": "Contact",
          "url": "https://www.addextherapeutics.com/en/about-us/contact/",
          "content": "# [![Addex](/themes/application/assets/media/images/addex-logo.svg)](/)\n\n## Allosteric modulators for **human health**\n\n# Contact\n\n**ADDEX THERAPEUTICS LTD and ADDEX PHARMA SA**\n\n**Office:**\n\nChemin des Mines, 9CH-1202 Geneva, Switzerland.Tel.:[+41 22 884 1555](tel:+41%2022%20884%201555)Fax: [+41 22 884 1556](http://fax:+41%2022%20884%201556/)\n\n**US Mailing Address:**\n\nAddex Pharmaceuticals Inc.1968 S Coast HWY #1915Laguna Beach, CA 92651, USA\n\n**Registered Office** :\n\nChemin Des Aulx 12Case Postale 68,1228 Plan-Les-OuatesSwitzerland\n\nFor Media inquiries: media.relations@addextherapeutics.comFor Investor inquiries: investor.relations@addextherapeutics.comTo send your CV: hr-recruitment@addexpharma.comFor Business Development: bd@addexpharma.comFor other inquiries: info@addextherapeutics.com\n\n## Contact form\n\nI am... Mr. Mrs. Ms. Dr. Prof.\n\nAll fields marked with an asterix (*) are required.\n\nSend message\n\n[ Back ](/)\n"
        }
      ]
    }
  ]
}